Prime Medicine
PRME
122 hedge funds and large institutions have $354M invested in Prime Medicine in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 19 closing their positions.
181% more call options, than puts
Call options by funds: $772K | Put options by funds: $275K
45% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 31
37% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 19
6% more funds holding
Funds holding: 115 → 122 (+7)
1.82% more ownership
Funds ownership: 55.58% → 57.39% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less capital invested
Capital invested by funds: $467M → $354M (-$113M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.21M |
| 2 |
Millennium Management
New York
|
+$5.43M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$3.85M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.67M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.86M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.92M |
| 3 |
Renaissance Technologies
New York
|
-$2.54M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.31M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.13M |
PRME Hedge Fund Activity: Q2 2024 in Review
122 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q2 2024, worth a combined $354M — down 24% from $467M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PRME positions and 19 closed out — a net gain of 7 holders — while 45 added to existing stakes and 31 trimmed.
The largest buyer was BlackRock, adding an estimated $8.21M. The largest seller was Avidity Partners Management, cutting an estimated $7.86M.
- 122 institutional investors held Prime Medicine (PRME) as of Q2 2024, up from 115 in Q1 2024.
- Funds reported $354M of Prime Medicine stock for Q2 2024, down 24% quarter-over-quarter.
- 26 funds opened new Prime Medicine positions in Q2 2024 and 19 closed out, a net change of +7 holders.
- The largest Prime Medicine buyer in Q2 2024 was BlackRock, an estimated $8.21M added.
- The largest Prime Medicine seller in Q2 2024 was Avidity Partners Management, an estimated $7.86M sold.
Based on aggregated 13F filings for Q2 2024.